Fast Facts: Biosimilars in Hematology and Oncology : Biologics and Biosimilars - Getting Decisions Right
Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days'exposure in Europe, shows that approved biosimilars can b...
| Autores principales: | , |
|---|---|
| Formato: | Libro |
| Publicado: |
S. Karger
2020
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=nlebk&AN=2396691&site=ehost-live header: @attributes: shortDbName: nlebk uiTerm: 2396691 longDbName: eBook Collection (EBSCOhost) uiTag: AN controlInfo: bkinfo: btl: Fast Facts: Biosimilars in Hematology and Oncology : Biologics and Biosimilars - Getting Decisions Right aug: au: Paul, Cornes Ali, McBride sertl: Fast Facts isbn: 9781912776214 9781912776221 9781912776238 imageinfo: pubinfo: dt: @attributes: year: 2020 month: 01 day: 01 dtAvail: @attributes: year: 2022 month: 04 day: 05 pub: S. Karger pubContract: Karger AG (Open Access) place: Basel price: 0.01 limitsGroup: maxCheckoutDays: 1500 pda: N printPagesOffline: 100 printPagesOnline: 100 previewPages: 10000 prePubGroup: dewey: @attributes: class: 615.1 item: 615 .1 lc: @attributes: class: RS380 item: RS 380 artinfo: ui: 2396691 1145603999 formats: fmt: – @attributes: type: EB doid: NL$2396691$PDF caption: PDF download: Y – @attributes: type: EK doid: NL$2396691$EPUB caption: EPUB download: Y tig: atl: Fast Facts: Biosimilars in Hematology and Oncology : Biologics and Biosimilars - Getting Decisions Right ptl: Fast Facts aug: au: Paul, Cornes Ali, McBride su: Oncology Bioengineering Pharmaceutical biotechnology Hematology Biotechnology sug: subj: MEDICAL / Chemotherapy Oncology Bioengineering Pharmaceutical biotechnology Hematology Biotechnology ab: Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days'exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options.'Fast Facts: Biosimilars in Hematology and Oncology'provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. pubtype: eBook doctype: Book ougenre: Book language: English copyright: @attributes: flag: N copyrightText: holdings: @attributes: islocal: N |
|---|